Summary by Moomoo AI
cspc pharma announced its mid-term report for 2024, showing growth in revenue and net profit attributable to shareholders of 1.3% and 1.7% respectively. During the period, the company declared a mid-term dividend of 16 Hong Kong cents per share, an increase of 14.3% compared to the same period last year. In addition, the company completed a total of 0.387 billion Hong Kong dollars in share repurchases in the first half of the year, and plans to repurchase up to a maximum of 1 billion Hong Kong dollars worth of shares. R&D investment increased by 10.3%, reflecting the company's continued investment in innovative drugs research and development. The company's shares were repurchased on the Hong Kong Stock Exchange in April and June 2024 and subsequently canceled in the following months, with the board of directors believing that this move will enhance shareholder value.
